Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Cellectis (CLLS) Shares Outstanding (2017 - 2025)

Cellectis (CLLS) posted Shares Outstanding of $18.0 million for Q4 2025, little changed on a QoQ basis from $18.0 million in Q4 2024, and little changed year-over-year from $18.0 million in Q4 2024.

Cellectis (CLLS) has 9 years of Shares Outstanding data on file, last reported at $18.0 million in Q4 2025.

  • In Q4 2025, Shares Outstanding changed 0.0% year-over-year to $18.0 million; the TTM figure through Dec 2025 stood at $18.0 million (changed 0.0% YoY), while the FY2025 annual figure was $18.0 million, changed 0.0% from the prior year.
  • Shares Outstanding steadied at $18.0 million in Q4 2025, from $18.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $71.8 million in Q4 2023 and bottomed at $10.0 million in Q4 2025.
  • A 5-year average of $39.7 million and a median of $46.6 million in 2022 frame the typical range for Shares Outstanding.
  • Annual changes were most pronounced in 2023 — Shares Outstanding surged 53.97% — and 2024, when it plunged 74.91%.
  • Year by year, Shares Outstanding stood at $52.0 million in 2021, then declined by 10.44% to $46.6 million in 2022, then soared by 53.97% to $71.8 million in 2023, then plunged by 74.91% to $18.0 million in 2024, then changed by 0.0% to $18.0 million in 2025.
  • The last three Shares Outstanding figures came in at $18.0 million (Q4 2025), $18.0 million (Q4 2024), and $71.8 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Outstanding (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 5.21 Mn
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 56.35 Mn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 91.57 Bn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 254.16 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 1.80 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 133.44 Mn
10 Cellectis 20.83 Bn 20.62 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 18.00 Mn
Dec 31, 2025 10.00 Mn
Dec 31, 2025 10.00 Mn
Dec 31, 2025 10.00 Mn
Dec 31, 2025 18.00 Mn
Dec 31, 2025 18.00 Mn
Dec 31, 2025 18.00 Mn
Dec 31, 2025 10.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2024 18.00 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2023 71.75 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2022 46.60 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2021 52.03 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2020 42.78 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2019 42.47 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2018 42.43 Mn
Dec 31, 2017 35.96 Mn
Dec 31, 2017 35.96 Mn
Dec 31, 2017 35.96 Mn
Dec 31, 2017 35.96 Mn
Dec 31, 2017 35.96 Mn
Dec 31, 2017 35.96 Mn
Dec 31, 2017 35.96 Mn
Dec 31, 2017 35.96 Mn